<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124526</url>
  </required_header>
  <id_info>
    <org_study_id>LNHF-03.</org_study_id>
    <secondary_id>04-0199</secondary_id>
    <secondary_id>2004/254</secondary_id>
    <nct_id>NCT01124526</nct_id>
  </id_info>
  <brief_title>Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma</brief_title>
  <official_title>Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociacion Espanola de Hematologia y Hemoterapia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociacion Espanola de Hematologia y Hemoterapia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the rituximab administration with
      fludarabine and cyclophosphamide results, are better, than the ones obtained with
      conventional therapy such as CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) and
      also to determine whether the rituximab administration as maintenance treatment during two
      years, increase the global clinical responses and the disease free time interval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of monoclonal antibodies, specifically the chimerical humanized anti-CD20 monoclonal
      antibody (Rituximab, MabThera®) represents one of the most innovative aspects in the indolent
      lymphoma treatment. Preliminary data show from 40% to 50% of response with a median response
      duration between 6 and 11 months in patients with relapsing FL. This response rate increase
      when rituximab is administered as initial treatment.

      Therefore, not only due to the clinical results but also to the tolerance, and based on an
      innovative mechanism of action and in its minimal toxicity, it seems reasonable to raise the
      possibility to incorporate the administration of the monoclonal antibody with
      chemotherapeutic agents.

      The development of a new treatment scheme that includes Rituximab administration within
      treatment protocols that combine fludarabine and cyclophosphamide, whose results are better
      than the ones obtained with conventional treatments such as CHOP, should increase the
      molecular response rate and contribute therefore to increase the disease-free time interval
      (time to progression), without adding any toxicity, in addition to achieve a higher
      proportion of clinical responses (as global as complete responses). In order to increase the
      time interval to progression, a maintenance treatment will be carried out for 2 years, which
      has shown an evident benefit in the time to progression in preliminary studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression disease</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free-disease period</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of RFC</measure>
    <time_frame>54 months</time_frame>
    <description>Toxicity is detailed and tabulate following the WHO classification. The safety analysis includes the incidence of adverse events (AE),vital signs and laboratory parameters.
Impact tables are made of AE following the classification of preferred term. Also include an analysis of the intensity of AE and their relation to the combiantion of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular monitoring of clinical response</measure>
    <time_frame>54 months</time_frame>
    <description>Study of t14:18 translocation with altered expression of BCL2.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab, Fludarabine, ciclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:
RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab Fludarabine Cyclophosphamide</intervention_name>
    <description>Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:
RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)</description>
    <arm_group_label>Rituximab, Fludarabine, ciclophosphamide</arm_group_label>
    <other_name>MABTHERA</other_name>
    <other_name>BENEFLUR</other_name>
    <other_name>GENOXAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated patients with grade I-III follicular lymphoma (grade B- D from
             the Working Formulation, centrofollicular lymphoma in the REAL classification),
             without evidence of histological transformation.

          -  Clinical diagnose by histological and/or immunophenotypical evaluation with positive
             results for CD 20 Mo Ab (node, bone marrow).

          -  Ann-Arbor stage II-IV.

          -  Male and female patients from 18 to 75 years old.

          -  Lack of related clinically uncontrolled diseases.

          -  Lack of VIH infection.

          -  Performance status (ECOG) of 0, 1, 2.

          -  Patients who voluntarily gave informed consent for the study participation.

          -  Life expectancy &gt; 3 months.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women.

          -  Women of childbearing age who do not accept to use an effective contraceptive method
             during the treatment and one year post-treatment.

          -  Immunodeficiency condition and autoimmune diseases.

          -  Patients with advanced clinically uncontrolled cardiac, hepatic or renal
             insufficiency, defined by the following criteria: total bilirubin, alkaline
             phosphatase or transaminases &gt;2 x upper limit of normal, and serum creatinine value &gt;2
             x upper limit of normal.

          -  Patients previously treated with chemotherapy or radiotherapy.

          -  History of oncologic disease within the last 5 years, apart from non-melanoma
             cutaneous neoplasia or carcinoma in situ of uterine cervix.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José F. Tomás, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E . Prieto Pareja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Hernández Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Díaz Mediavilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Montalbán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Javier Peñañver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. De La Serna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Carmen Burgaleta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Sánchez Godoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Dolores Monteagudo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Fernández De Sevilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Jesús Peñarrubia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Dolores Caballero Barrigón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Bajo Gómez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Paz Coll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. A. Queizán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Cabrera Silva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>O. Arija, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Bravo Barahona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Salar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <state>Badajoz_Extremadura</state>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona_ Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología (ICO)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona_Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <state>Cáceres_Extremadura</state>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz_ Andalucía</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Xeral_Calde</name>
      <address>
        <city>Lugo</city>
        <state>Lugo_ Galicia</state>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28943</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Móstoles</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Salamanca_Castilla León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <state>Segovia_ Castilla León</state>
        <zip>40001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico del Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <state>Valladolid_Castilla León</state>
        <zip>47010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Internacional España</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <last_update_submitted>May 14, 2010</last_update_submitted>
  <last_update_submitted_qc>May 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>JF Tomás / MD</name_title>
    <organization>Asociación Española de Hematología y Hemoterapia</organization>
  </responsible_party>
  <keyword>R F C treatment in patients with Non Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

